Home   ->   news   ->   Press Releases

Press Releases

WuXi PharmaTech's SynTheAll Passes ISO 9001:2000 Quality Management Certification Audit

December 14, 2005 - Shanghai, China - SynTheAll Pharmaceuticals (STA), a wholly owned subsidiary of WuXi PharmaTech, today announced it has successfully passed ISO 9001:2000 audit by SGS. STA, located in Jinshan District of Shanghai, received the certification for its 250,000 square feet facility that manufactures pharmaceutical intermediates and active pharmaceutical ingredients (API) under GMP conditions.

SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With 42,000 employees, SGS operates a network of about 1,000 offices and laboratories around the world.

ISO is a network of the national standards institutes of 156 countries. ISO standards specify the requirements for state-of-the-art products, services, processes, materials and systems, and for good conformity assessment, managerial and organizational practice. ISO 9001:2000 is based on eight quality management principles: customer focus, leadership, involvement of people, process approach, system approach, continual improvement, fact based decision making, and mutually beneficial supplier relationships.

"SynTheAll's ISO 9001:2000 certification exemplifies our commitment to quality and customer satisfaction as well as continuously improving our quality systems, integrating the realities of a changing world," said Mr. Jagdish Sastry, Chief Operating Officer of SynTheAll, "We are continually using, monitoring and improving our management system and processes so as to meet or exceed customer satisfaction and delivery requirements. It is every STA employee's ongoing concern to keep their sights on every operational detail and to enhance accuracy and efficiency."

About WuXi PharmaTech (Cayman) Inc. WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.

back to top